睿知中国医院研究地图
候选清单

即将招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07594899,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 12 months after final dose of treatment

    排除标准第 14 条

  3. ECOG Performance Status of 0, 1, or 2

    入选标准第 3 条

  4. Absolute neutrophil count <1.0 × 10⁹/L.

    排除标准第 5 条

    Platelet count <75 × 10⁹/L

    排除标准第 6 条

    Serum AST and ALT ≥ 2.5 x ULN

    排除标准第 7 条

    Total bilirubin ≥ 1.5 x ULN

    排除标准第 8 条

    Serum creatinine clearance < 30 mL/min (using Cockcroft-Gault formula)

    排除标准第 9 条

  5. At least 1 measurable site of disease (defined as lymph nodes with the long diameters longer than 1.5cm, or extra-nodal sites with the long diameters longer than 1.0cm; meanwhile, any lesion site with at least 2 measurable vertical diameters)

    入选标准第 6 条

  6. Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing):Participants positive for HCV antibody are eligible only if PCR is negative for HCV RNA

    排除标准第 12 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07594899,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age 18-75 years with comprehensive geriatric assessment stratified as fit
  2. Previously untreated participants with CD20-positive LBCL (without central nervous system involvement)
  3. ECOG Performance Status of 0, 1, or 2
  4. After 1 cycle of Pola-R-CHP, classified as intermediate-risk or high-risk by AI-based multimodal stratification
  5. Life expectancy ≥ 3 months
  6. At least 1 measurable site of disease (defined as lymph nodes with the long diameters longer than 1.5cm, or extra-nodal sites with the long diameters longer than 1.0cm; meanwhile, any lesion site with at least 2 measurable vertical diameters)
  7. The patient or his or her legal representative must provide written informed consent prior to any special examination or procedure for the research.
  8. Anti-lymphoma drugs have not been used before (except glucocorticoids)

排除标准:Exclusion Criteria:

  1. Prior solid organ transplantation or SCT
  2. Significant or extensive history of cardiovascular disease such as New York Heart Association Class III or IV cardiac disease or Objective Assessment Class C or D, myocardial infarction within the last 6 months prior to the start of Cycle 1, unstable arrhythmias, or unstable angina
  3. History or presence of an abnormal ECG that is clinically significant in the investigator's opinion
  4. Any of the following abnormal laboratory values (unless any of these abnormalities are due to underlying lymphoma):
  5. Absolute neutrophil count <1.0 × 10⁹/L.
  6. Platelet count <75 × 10⁹/L
  7. Serum AST and ALT ≥ 2.5 x ULN
  8. Total bilirubin ≥ 1.5 x ULN
  9. Serum creatinine clearance < 30 mL/min (using Cockcroft-Gault formula)
  10. Any active infection within 7 days prior to Cycle 1 Day 1 that would impact participant safety
  11. Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen [HBsAg] serology):Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HbsAg) may be included if hepatitis B virus (HBV) DNA is undetectable at the time of screening. Such participants must be willing to undergo HBV DNA testing every month and appropriate antiviral therapy as indicated
  12. Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing):Participants positive for HCV antibody are eligible only if PCR is negative for HCV RNA
  13. Participants with a history of progressive multifocal leukoencephalopathy
  14. Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 12 months after final dose of treatment
  15. Participants with uncontrolled coagulation disorders, connective tissue diseases, severe infectious diseases
  16. Other concurrent and uncontrolled medical conditions that, in the opinion of the investigator, would affect the patient's participation in the study

引自 ClinicalTrials.gov, NCT07594899, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07594899,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07594899